Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors

Abstract Cancer testis tumour associated antigens (C/T-TAAs) were investigated in several gynaecologic and non-gynaecologic neoplasms as possible prognostic markers and targets for immunotherapy. The objective of the present study was to evaluate C/T-TAA expression patterns and prognostic significan...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2007-11, Vol.43 (17), p.2621-2627
Main Authors: Bellati, Filippo, Napoletano, Chiara, Tarquini, Elisabetta, Palaia, Innocenza, Landi, Rachele, Manci, Natalina, Spagnoli, Giulio, Rughetti, Aurelia, Panici, Pierluigi Benedetti, Nuti, Marianna
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm - metabolism
Biological and medical sciences
Cancer testis tumour associated antigens
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Immunohistochemistry
Lymphatic Metastasis
MAGE-A
Medical sciences
Melanoma-Specific Antigens
Membrane Proteins - metabolism
Middle Aged
Neoplasm Proteins - metabolism
Neoplasm Recurrence, Local - metabolism
NY-ESO-1
Pharmacology. Drug treatments
Prognosis
Tumors
Vulvar cancer
Vulvar Neoplasms - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cancer testis tumour associated antigens (C/T-TAAs) were investigated in several gynaecologic and non-gynaecologic neoplasms as possible prognostic markers and targets for immunotherapy. The objective of the present study was to evaluate C/T-TAA expression patterns and prognostic significance in patients affected by vulvar cancer. Melanoma antigen E (MAGE)-A1, MAGE-A4 and NY-ESO-1 expression was determined by immunohistochemistry in paraffin-embedded tissue specimens from 45 primary and 14 recurrent vulvar carcinomas treated with surgery. MAGE-A1, MAGE-A4 and NY-ESO-1 were expressed in 25 (42%), 38 (64%) and 40 (68%) of the 59 samples, respectively. MAGE-A4 was significantly more frequently expressed in tumours with lymph node metastases ( p < 0.002) and in recurrent tumours ( p < 0.02). NY-ESO-1 was more highly expressed by moderately or poorly differentiated tumours ( p < 0.01). This study demonstrates that vulvar cancer frequently expresses C/T-TAAs. Antigen expression correlates with the presence of lymph node metastases and poor tumour differentiation.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2007.08.031